Please login to the form below

Not currently logged in
Email:
Password:

skin cancer

This page shows the latest skin cancer news and features for those working in and with pharma, biotech and healthcare.

Keytruda is first I-O drug cleared for melanoma in China

Keytruda is first I-O drug cleared for melanoma in China

Opdivo (nivolumab) in the much-larger non-small cell lung cancer (NSCLC) indication last month. ... new therapies for the skin cancer in China that extends back decades, according to Professor Jun Guo of Peking University Cancer Hospital.

Latest news

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    The drug – sold as Bavencio – has been approved for skin cancer Merkel cell carcinoma and bladder cancer, but in February failed a trial as a second-line therapy for non-small ... cell lung cancer and also had a knockback in third-line stomach cancer

  • Regeneron’s Dupixent and Praluent falls short Regeneron’s Dupixent and Praluent falls short

    an FDA verdict in skin cancer in October but will be sixth in the class to market. ... The drug is backed up by a series of bispecific antibodies for cancer indications.

  • J&J pays $140m upfront for cancer-busting virus firm BeneVir J&J pays $140m upfront for cancer-busting virus firm BeneVir

    cancer, but also because it has to be injected directly into tumours rather than systemically, increasing the complexity of treatment. ... that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer

  • Sanofi’s latecomer PD-1 gets date for FDA verdict Sanofi’s latecomer PD-1 gets date for FDA verdict

    The FDA has set a deadline of 28 October for its review of Sanofi’s cemiplimab for a form of skin cancer, as the company tries to join the fast-growing ... The US regulator has given a priority review for PD-1-targeting cemiplimab because its first

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    drug. Opdivo and Yervoy have already shown their worth in melanoma, with BMS claiming approval for the combination in that form of skin cancer in 2015, and is also being tested ... Roche has also reported Sutent-topping results with it’s combination of

More from news
Approximately 17 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • Digital health Digital health

    What digital health has delivered to date is amazing. The examples are legion: an application which can differentially diagnose lesions on skin with 20-30 times more accuracy than a doctor ... when it comes to skin cancer, or HealthTap’s Dr AI which

  • Case study: Skin cancer awareness

    Skin cancer is on the increase. It is one of the most common cancers in the 15-24 age group and a significant cause of death. ... Posters and leaflets do not get through to younger people; at this age they feel invincible and believe skin cancer will

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • CytomX appoints Rachel Humphrey chief medical officer CytomX appoints Rachel Humphrey chief medical officer

    Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Keith Nolop joins US cancer biotech from Plexxikon. Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief ... At Plexxikon, he also led the filing of eight

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Is fear an effective driver of behaviour change?

    Liz, who knows she has a high risk for skin cancer due to family history and skin type, will be more likely to apply sun cream (provided it is easy for ... Leo, who knows he has a lower risk of skin cancer, or for whom the cost or convenience of applying

  • When is sun safety doing more harm than good?

    New figures from  Cancer Research UK  warn that people over 65 are around seven times more likely to develop malignant melanoma - a type of skin cancer - compared to 40 years ago. ... Thankfully campaigns from charities such as Cancer Research UK

  • Market Insights Can Deliver a Better Patient Experience

    Cancer Research UK’s Sunsmart campaign knew from their research that health safety messages were not going to change the behavior of young people who use sunbeds to tan their skin. ... This audience are more concerned about their looks than about the

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics